<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510976</url>
  </required_header>
  <id_info>
    <org_study_id>S53094</org_study_id>
    <nct_id>NCT02510976</nct_id>
  </id_info>
  <brief_title>Prucalopride Versus Placebo in Gastroparesis</brief_title>
  <official_title>Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled cross-over study of prucalopride 2 mg daily or placebo in gastroparesis
      (idiopathic or diabetic). Patients will be randomized to 4 week treatment with the first
      regimen (double-blind), followed by a 2-week washout and 4 week treatment with the second
      regimen in cross-over.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the influence of prucalopride (Resolor®) 2mg daily, 30 patients with idiopathic and
      30 patients with diabetic gastroparesis will undergo two gastric emptying breath tests with
      concomitant assessment of meal-related symptoms, at the conclusion of two consecutive, 4-week
      treatment periods of prucalopride or placebo. The order of prucalopride and placebo treatment
      will be randomised at the initiation of the study. Medication for both patient groups, 30
      patients with idiopathic and 30 patients with diabetic gastroparesis, will be randomized
      separately. Half of the subjects will receive placebo first; the other half will receive
      prucalopride first. Treatment periods will be separated by a wash-out period of 2 weeks. All
      drugs potentially affecting gastrointestinal motility or sensitivity will be discontinued at
      least two weeks prior to the initiation of the study. Informed consent will be obtained from
      each participant.

      In order to establish the gastrointestinal symptom and quality-of-life profile of this
      cohort, each patient will complete the following validated self-reported instruments at
      baseline and at each of the two testing visits (table 1): Patients assessment of
      Gastrointestinal symptoms (PAGISYM), Patients assessment of Gastrointestinal Quality of Life
      Impact (PAGIQoL) Gastrointestinal and Global Severity Score, Patient Health Questionnaire
      (PHQ-15), Appetite Questionnaire, Hospital Anxiety and Depression Scale, Visceral Sensitivity
      Index, Short Form Nepean Dyspepsia Index (SF-NDI). The PAGI-SYM is a comprehensive
      questionnaire of upper GI symptoms, and it includes a gastroparesis questionnaire module: the
      Gastroparesis Cardinal Symptom Index (GCSI), which has been validated in (idiopathic)
      gastroparesis.26 Furthermore, during the entire study duration patients will complete a daily
      symptom diary, incorporating a separate horizontal 100-mm visual analogue scale (VAS) for
      each of 9 upper abdominal symptoms. As prucalopride has a well-known therapeutic effect in
      chronic constipation, patients will also register information about their stool frequency and
      stool type in the daily diary (Bristol Stool Scale).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GCSI questionnaire score</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>validated gastroparesis questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PAGI SYM questionnaire scores</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>validated upper GI questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NDI questionnaire scores</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>validated upper GI QOL questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric half emptying time</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>gastric emptying test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily diary symptom and stool pattern scores</measure>
    <time_frame>over 4 weeks, weekly average</time_frame>
    <description>daily symptom diaries</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>over 4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prucalopride tablet 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prucalopride</intervention_name>
    <arm_group_label>Prucalopride</arm_group_label>
    <other_name>Resolor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients with a previously established diagnosis of diabetes or functional
             dyspepsia according to Rome III criteria, and with delayed gastric emptying (t1/2 for
             solids ≥ 109 min) on a breath test

        Exclusion Criteria:

          -  The presence of oesophagitis, gastric atrophy or erosive gastroduodenal lesions on
             endoscopy

               -  the presence of lesions on small bowel X-ray

               -  major abdominal surgery

               -  underlying psychiatric illness

               -  use of non-steroidal anti-inflammatory drugs, steroids, or drugs affecting
                  gastric motility.

               -  Major co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Tack, M.D., Ph.D.</last_name>
    <phone>+3216344228</phone>
    <email>jan.tack@med.kuleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Leuven</city>
        <state>Vlaanderen</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Tack, M.D., Ph.D.</last_name>
      <phone>+3216344225</phone>
      <email>jan.tack@med.kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Jan Tack, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

